Your session is about to expire
← Back to Search
Durvalumab + Radiation for Small Cell Lung Cancer
Study Summary
This trial will explore if combining radiation with durvalumab, carboplatin and etoposide can help treat extensive-stage small cell lung cancer. Participation lasts 48 months.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I weigh more than 30 kilograms.I am eligible for platinum-based chemotherapy as my first treatment for extensive small cell lung cancer.I am not pregnant or breastfeeding and willing to use birth control during and up to 90 days after treatment.You have had an organ transplant from someone else.I don't have lasting side effects from cancer treatment, except for hair loss or skin changes.I haven't had major surgery in the last 28 days, except for minor procedures to relieve symptoms.You are expected to live for at least 12 more weeks.I do not have any serious ongoing illnesses that could affect my participation in the study.I can care for myself and am up and about more than 50% of my waking hours.I do not have active infections like TB, hepatitis B, C, or HIV.I agree to use birth control during and for 4 months after the study.I had cancer before, but it was treated over 5 years ago and is not likely to come back.I am using hormone therapy for reasons other than cancer.I have not received a live vaccine in the last 30 days.I can sign and follow the study's consent form and rules.I am willing and able to follow the study's treatment and visit schedule.I have a condition related to my cancer that affects other parts of my body and requires strong medication.I am using two birth control methods or am not having sex to join this study.I have been treated with medications targeting PD-1/PD-L1 or CTLA4.My brain metastases are stable without needing steroids or seizure medicine for 2 weeks.My lung cancer has spread to other parts of my body.I haven't had extensive radiation to my bone marrow or wide field radiation in the last 4 weeks.You have a history of a weakened immune system that is currently active.I haven't taken immunosuppressive drugs in the last 14 days.I am older than 18 years.I've had significant radiation therapy to the area that will be treated in this trial.I have had treatments like chemotherapy or radiation for small cell lung cancer.My blood tests show my organs and bone marrow are working well.I have or had an autoimmune or inflammatory disorder.I have a tumor that can be measured and is suitable for targeted radiation therapy.
- Group 1: Participants With Extensive Small Cell Lung Cancer (All Participants)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for the trial still open?
"As per the information on clinicaltrials.gov, this research is looking for volunteers and has been in operation since August 19th of 2022 with a recent update occurring on February 14th 2023."
Has the application for Participants With Extensive Small Cell Lung Cancer (All Participants) been accepted by the FDA?
"Our collective sentiment at Power is that Participants With Extensive Small cell lung cancer (All Participants) have the safety rating of 2, as it has been tested in Phase 2 clinical trials and only preliminary evidence for its efficacy exists."
Have any experiments been conducted that included patients diagnosed with extensive small cell lung cancer?
"At present, 1091 clinical trials for Participants With Extensive Small cell lung cancer (All Participants) are live with 293 of those trials in the most advanced phase. Although a number of these studies can be located in Orlando, Florida, there is an expansive network of 58978 research centres researching this disease across the world."
What health concerns can be addressed by Participants With Extensive Small Cell Lung Cancer (All Participants)?
"Patients with Extensive Small cell lung cancer (All Participants) often receive this medication to address recurrent cancers. It is also used off-label for advanced cervical cancer, gestational trophoblastic disease and other medical concerns."
What is the current enrollment number for this clinical trial?
"Affirmative. Clinicaltrials.gov attests that this research study, which was initially posted on August 19th 2022, is presently recruiting individuals for participation. 49 people are needed to be enrolled from a solitary medical location."
Share this study with friends
Copy Link
Messenger